Canada Cardiovascular Drugs Market by Drug Classification (Branded, Generic), By Disease Indication (Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others), By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCanada Cardiovascular Drugs Market by Drug Classification (Branded, Generic), By Disease Indication (Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others), By End User (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2028
For instance, as per the data published by the Heart and Stroke Foundation Canada in February 2022, 750,000 people had a heart failure and 100,000 people are diagnosed with this incurable condition each year in Canada.
Growing Prevalence of Cardiovascular Diseases
The increasing prevalence of cardiovascular diseases is a major driver of growth in the Canadian Cardiovascular Drugs Market. Cardiovascular diseases are a leading cause of death in Canada, and the aging population and unhealthy lifestyle habits, such as poor diet and lack of exercise, are contributing to the rising prevalence of these diseases.
Increasing healthcare expenditure
Increasing healthcare expenditure is another key factor driving the growth of the Canada Cardiovascular Drugs Market. The Canadian government is investing in significant resources in healthcare, including cardiovascular care. This has led to improved access of cardiovascular drugs for patients.
Growing adoption of combination therapies
The growing adoption of combination therapies is a key factor influencing the growth of the Canada cardiovascular drugs market. Combination therapies are drug regimens that combine two or more drugs with different mechanisms of action to achieve a more comprehensive treatment approach.
Combination therapy for heart failure may include drugs that target different pathways, such as angiotensin receptor blockers and beta-blockers, to improve cardiac function.
Growing Advancements in drug development
Advancements in technology are a major factor influencing the growth of the Canada Cardiovascular Drugs Market. The development of new technologies has led to the discovery of new drugs and improved treatment options for cardiovascular diseases. In addition, technology has made it possible to deliver cardiovascular drugs more effectively and efficiently, improving patient outcomes and reducing healthcare costs.
Personalized medicine is an approach that involves tailoring treatment to an individual's genetic and molecular profile. This approach can lead to more effective treatment options and reduce the risk of adverse events. Advancements in genetic testing and biomarker identification have made it possible to identify patients who are most likely to benefit from specific drugs, improving treatment outcomes.
Another area of technological advancement in the cardiovascular drugs market is drug delivery systems. Drug delivery systems can improve the efficacy of cardiovascular drugs by delivering them directly to the site of action. For example, drug-eluting stents can be used to deliver drugs to the site of a blockage in the coronary artery, reducing the risk of restenosis. Inhalation therapy is being developed for the treatment of pulmonary hypertension, which can improve drug delivery to the lungs.
Growing Demand for Personalized Medicine Drives the Growth of the Market
Personalized medicine is a key driver of growth in the Canada Cardiovascular Drugs Market. Personalized medicine involves the use of a patient's genetic and molecular profile to tailor treatment to their specific needs, leading to more effective and targeted therapies. This approach has significant potential in the treatment of cardiovascular diseases, where individual variations in response to treatment can be significant.
Genetic testing can identify patients with familial hypercholesterolemia, a genetic condition that results in high levels of low-density lipoprotein cholesterol (LDL-C). These patients are often unresponsive to traditional lipid-lowering therapies and require more aggressive treatment with statins or other cholesterol-lowering drugs.
Increasing Awareness about novel drugs and therapies propel the growth of the market.
Increasing awareness of cardiovascular diseases among aging population and the importance of early detection and treatment is expected to drive the growth of Canadian cardiovascular drugs market over the years. As more people become aware of the risks associated with cardiovascular diseases, they are seeking out preventive measures and treatment options, which is driving demand for cardiovascular devices.
Recent Development
·
·
·
Market Segmentation
The Canada Cardiovascular Drugs Market can be segmented by drug classification, disease indication, end user, and region. Based on drug classification, the market can be divided into branded and generic. Based on disease indication, the market can be segmented into hypertension, coronary artery disease, hyperlipidaemia, arrhythmia, and others. Based on end user, the market can be grouped into hospital pharmacies, online pharmacies, retail pharmacies, and others.
Market Players
Bristol-Myers Squibb Canada Co, Pfizer Canada., Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Canada Inc, Merck & Co Inc., AstraZeneca Canada Inc., Sanofi-Aventis Canada Inc., Gilead Sciences Canada, Inc., Hoffmann-La Roche Limited. are some of the leading players operating in the Canada Cardiovascular Drugs Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By By By End User By Region |
| Regional scope | Ontario region; Quebec region; Alberta region; British Columbia region; Saskatchewan and Manitoba region; Rest of Canada |
| Key companies profiled | Bristol-Myers Squibb Canada Co, Pfizer Canada., Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Canada Inc, Merck & Co Inc., AstraZeneca Canada Inc., Sanofi-Aventis Canada Inc., Gilead Sciences Canada, Inc., Hoffmann-La Roche Limited |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy